| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4111342
Max Phase: Preclinical
Molecular Formula: C10H21NO5
Molecular Weight: 235.28
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: CCOCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
Standard InChI: InChI=1S/C10H21NO5/c1-2-16-4-3-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1
Standard InChI Key: MNSFMAWUKDBQJX-UTINFBMNSA-N
Associated Targets(non-human)
Lysosomal alpha-glucosidase 58 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 235.28 | Molecular Weight (Monoisotopic): 235.1420 | AlogP: -2.22 | #Rotatable Bonds: 5 |
| Polar Surface Area: 93.39 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 4 |
| #RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 12.90 | CX Basic pKa: 7.64 | CX LogP: -2.19 | CX LogD: -2.63 |
| Aromatic Rings: 0 | Heavy Atoms: 16 | QED Weighted: 0.40 | Np Likeness Score: 0.82 |
References
| 1. (2015) Method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives, |
Source
Source(1):